|
Passage Bio, Inc. (PASG): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Passage Bio, Inc. (PASG) Bundle
In the cutting-edge world of biotechnology, Passage Bio, Inc. emerges as a pioneering force transforming rare neurological disease treatment through groundbreaking gene therapies. By leveraging their innovative PBLA platform and focusing on devastating genetic disorders like GM1 gangliosidosis and Krabbe disease, this Philadelphia-based company is pushing the boundaries of precision genetic medicine. Investors and medical professionals are watching closely as Passage Bio advances its clinically promising AAV-based therapies, offering hope to patients with previously untreatable neurodegenerative conditions and potentially revolutionizing genetic treatment paradigms.
Passage Bio, Inc. (PASG) - Marketing Mix: Product
Gene Therapy Product Development
Passage Bio, Inc. specializes in developing advanced gene therapies targeting rare neurological disorders. The company's product portfolio focuses on precision genetic treatments using their proprietary PBLA platform.
Primary Disease Targets
| Disease | Classification | Development Stage |
|---|---|---|
| GM1 Gangliosidosis | Rare Genetic Disorder | Phase 1/2 Clinical Trial |
| Krabbe Disease | Rare Neurological Condition | Preclinical Development |
| Frontotemporal Dementia | Neurodegenerative Disorder | Phase 1 Clinical Trial |
Product Technology Platform
The company utilizes AAV-based gene therapy vectors with specific characteristics:
- Proprietary PBLA platform for precision genetic treatments
- Advanced viral vector engineering
- Targeted neurological disease interventions
Clinical Pipeline Details
| Program | Indication | Preclinical | Phase 1 | Phase 2 |
|---|---|---|---|---|
| PBLA-001 | GM1 Gangliosidosis | Completed | Ongoing | Planned |
| PBLA-002 | Krabbe Disease | Ongoing | Pending | Not Started |
| PBLA-003 | Frontotemporal Dementia | Completed | Ongoing | Planned |
Therapeutic Approach
Passage Bio focuses on rare neurological genetic disorders with significant unmet medical needs, developing targeted gene therapy interventions.
Passage Bio, Inc. (PASG) - Marketing Mix: Place
Headquarters and Primary Location
Passage Bio, Inc. is headquartered at 2929 Arch Street, Suite 300, Philadelphia, Pennsylvania 19104, United States.
Research and Development Facilities
| Location | Facility Type | Focus Area |
|---|---|---|
| Philadelphia, PA | Primary R&D Center | Gene therapy research |
Clinical Trial Sites
Global Research Center Distribution
- United States research centers
- European research networks
Distribution Channels
| Channel Type | Target Market | Geographic Reach |
|---|---|---|
| Specialized neurology treatment networks | Rare genetic disorder patients | North America and Europe |
Market Targeting
Primary Geographic Markets
- North America
- European Union countries
Specialized Treatment Networks
Collaborating with specialized neurology treatment centers and rare disease research institutions.
Passage Bio, Inc. (PASG) - Marketing Mix: Promotion
Engaging with Rare Disease Patient Advocacy Groups
Passage Bio actively collaborates with rare neurological disease patient advocacy organizations to raise awareness and support research initiatives.
| Patient Advocacy Group | Collaboration Focus | Engagement Metrics |
|---|---|---|
| National MLD Foundation | Gene therapy research support | 3 joint awareness campaigns in 2023 |
| GM1 Gangliosidosis Research Foundation | Clinical trial recruitment | 2 collaborative research symposiums |
Presenting Research at Major Neuroscience and Genetic Medicine Conferences
Passage Bio presents scientific findings at key industry conferences to showcase research advancements.
| Conference | Year | Presentations |
|---|---|---|
| American Society of Gene & Cell Therapy Annual Meeting | 2023 | 4 scientific presentations |
| International Neurogenetics Conference | 2023 | 3 research poster sessions |
Utilizing Targeted Medical Communications
Targeted communications strategy for neurological specialists:
- Peer-reviewed journal publications: 6 in 2023
- Direct physician outreach programs
- Specialized medical webinar series
Leveraging Investor Relations and Biotech Industry Media Platforms
Media and investor communication strategy details:
| Platform | Engagement Metrics | Reach |
|---|---|---|
| Quarterly Earnings Calls | 4 calls in 2023 | Over 150 institutional investors |
| Biotech Industry Press Releases | 12 press releases in 2023 | Distributed across 25+ financial media platforms |
Conducting Educational Webinars and Scientific Symposiums
Scientific education and knowledge sharing initiatives:
- 8 scientific webinars in 2023
- 2 international symposiums on rare neurological diseases
- Average webinar attendance: 120 medical professionals
Passage Bio, Inc. (PASG) - Marketing Mix: Price
Financial Overview
As of Q4 2023, Passage Bio reported:
- Cash and cash equivalents: $234.7 million
- Research and development expenses: $87.4 million for the fiscal year
- Net loss: $116.5 million for the fiscal year
Stock Performance
| Date | Stock Price | Market Capitalization |
|---|---|---|
| January 2024 | $2.87 | $184.3 million |
| December 2023 | $3.12 | $199.6 million |
Funding Sources
Passage Bio's pricing strategy is primarily driven by:
- Venture capital investments
- Public stock offerings
- Research grants
- Collaboration agreements
Investment Valuation Metrics
| Metric | Value |
|---|---|
| Price to Book Ratio | 1.2 |
| Enterprise Value | $168.9 million |
| Research Grant Funding | $12.3 million in 2023 |
Clinical Trial Funding
Total investment in clinical trials: $65.2 million in 2023, focused on gene therapies for genetic disorders.
Pricing Strategy Components
- No current commercial product revenue
- Pricing dependent on future FDA approvals
- Potential gene therapy pricing based on rare disease market trends
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.